The FDA approved combined dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect, a condition characterized by inappropriate and involuntary laughing or crying, in 2010.
The approval was based on studies that evaluated the drug combination in patients with amyotrophic lateral sclerosis or multiple sclerosis.
This activity is supported by an educational grant from Genentech, Inc.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.